Entelos, a San Mateo, California-based provider of in silico modeling and simulation products and services that help pharmaceutical and consumer product companies make informed decisions in their product development process, has completed a recapitalization and has received a significant capital infusion of undisclosed amount.
The round was led by Clearlake Capital Group, with participation from existing investor Imperium Partners Group.
The company intends to use the funding to continue developing its products and services, and expand its sales and marketing efforts.
In conjunction with the transaction, Steve Chang, Clearlake Founding Partner, and Prashant Mehrotra, a Vice President at Clearlake, have joined the company’s Board of Directors.
Led by CEO Shawn O’Connor, Entelos is an in silico modeling and simulation software and services company delivering advanced predictive technologies designed to lower the risk, time, and cost of product development in the pharmaceutical, healthcare, nutrition and consumer markets.